| 1 |
34272712 | Case Study 5: Predicting the Drug Interaction Potential for Inhibition of CYP2C8 by Montelukast. | 2021 |
1 |
| 2 |
28940478 | Comprehensive Pharmacogenomic Study Reveals an Important Role of UGT1A3 in Montelukast Pharmacokinetics. | 2018 Jul |
1 |
| 3 |
29171020 | Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8-Mediated Metabolism of Montelukast in Humans. | 2018 Sep |
2 |
| 4 |
29870591 | Amenamevir: Studies of Potential CYP2C8- and CYP2B6-Mediated Pharmacokinetic Interactions With Montelukast and Bupropion in Healthy Volunteers. | 2018 Nov |
1 |
| 5 |
30117405 | In Vitro Drug-Drug Interaction Potential of Sulfoxide and/or Sulfone Metabolites of Albendazole, Triclabendazole , Aldicarb, Methiocarb, Montelukast and Ziprasidone. | 2018 |
1 |
| 6 |
27599706 | Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes. | 2017 Apr |
1 |
| 7 |
27648490 | Transporter-Mediated Hepatic Uptake Plays an Important Role in the Pharmacokinetics and Drug-Drug Interactions of Montelukast. | 2017 Mar |
4 |
| 8 |
28238899 | Estimation of the Contribution of CYP2C8 and CYP3A4 in Repaglinide Metabolism by Human Liver Microsomes Under Various Buffer Conditions. | 2017 Sep |
1 |
| 9 |
26581561 | Identification of putative substrates for cynomolgus monkey cytochrome P450 2C8 by substrate depletion assays with 22 human P450 substrates and inhibitors. | 2016 Jul |
3 |
| 10 |
26721703 | Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. | 2016 Jan |
1 |
| 11 |
25595597 | A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement. | 2015 Apr |
1 |
| 12 |
26374173 | In Vitro Metabolism of Montelukast by Cytochrome P450s and UDP-Glucuronosyltransferases. | 2015 Dec |
3 |
| 13 |
24523125 | Case study 4. Predicting the drug interaction potential for inhibition of CYP2C8 by montelukast. | 2014 |
1 |
| 14 |
21838784 | CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast. | 2012 Feb |
6 |
| 15 |
20931329 | The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast. | 2011 Feb |
2 |
| 16 |
21289076 | Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. | 2011 May |
10 |
| 17 |
20592724 | Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast. | 2010 Aug |
5 |
| 18 |
18413310 | Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. | 2008 Jun 20 |
1 |
| 19 |
18787056 | Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro. | 2008 Dec |
1 |
| 20 |
16981900 | Effect of multiple doses of montelukast on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in humans. | 2007 Mar |
3 |
| 21 |
16513447 | Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide. | 2006 Mar |
1 |
| 22 |
16670899 | Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone. | 2006 Jul |
1 |
| 23 |
15608135 | Selective inhibition of human cytochrome P4502C8 by montelukast. | 2005 Mar |
7 |